<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="editorial" dtd-version="2.3">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fphar.2020.00061</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Therapeutic Index for Nutraceuticals in Inflammation-Related Diseases: Efficacy, Bioavailability, Metabolism and Interactions With Drugs</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Peluso</surname><given-names>Ilaria</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/572115"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Palmery</surname><given-names>Maura</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/594793"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Research Centre for Food and Nutrition, Council for Agricultural Research and Economics (CREA-AN)</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Physiology and Pharmacology &#x201c;V. Erspamer,&#x201d; La Sapienza University of Rome</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited and reviewed by: Dieter Steinhilber, Goethe University Frankfurt, Germany</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Ilaria Peluso, <email xlink:href="mailto:ilaria.peluso@crea.gov.it">ilaria.peluso@crea.gov.it</email></p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>02</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>61</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>12</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>01</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2020 Peluso and Palmery</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Peluso and Palmery</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/8685/therapeutic-index-for-nutraceuticals-in-inflammation-related-diseases-efficacy-bioavailability-metabolism-and-interactions-with-drugs" ext-link-type="uri">Editorial on the Research Topic <article-title>Therapeutic Index for Nutraceuticals in Inflammation-Related Diseases: Efficacy, Bioavailability, Metabolism and Interactions With Drugs</article-title>
</related-article>
<kwd-group>
<kwd>phytochemicals</kwd>
<kwd>microbiota</kwd>
<kwd>cancer</kwd>
<kwd>oxidative stress</kwd>
<kwd>polypharmacy</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="2"/>
<word-count count="499"/>
</counts>
</article-meta>
</front>
<body>
<p>It has been suggested that some plant-derived phytochemicals from food or medicinal herbs could be therapeutically effective agents in the prevention and/or management of cancer and noncommunicable diseases associated with oxidative stress and inflammation.</p>
<p>In this issue, the anti-inflammatory effect of plant ingredients has been investigated by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.01186">Balkrishna et al.</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.00180">Cui et al.</ext-link>, and <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2018.01268">Ibrahim et al.</ext-link> <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.01186">Balkrishna et al.</ext-link> reported anti-inflammatory and antipsoriatic effects of a sea buckthorn oil (SBKT) derived from the fruit pulp of <italic>Hippophae rhamnoides</italic> in the carrageenan-stimulated rat paw edema model and in the 12-O tetradecanoyl phorbol 13-acetate (TPA) stimulated psoriasis-like lesion mice model, respectively. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.00180">Cui et al.</ext-link> observed an attenuation of the lipopolysaccharide (LPS)-induced duodenum histopathology changes in the mice treated with <italic>Gardenia jasminoide</italic>s decoction. On the other hand, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2018.01268">Ibrahim et al.</ext-link> investigated the nephroprotective efficacy of the two pure compounds benzyl isothiocyanate (BITC) and resveratrol (RES), as well as their combination, against cisplatin-induced acute renal injury in mice. The treatment with BITC and RES combination had the higher nephroprotective effects compared to both BITC and RES alone. In these studies, in addition to the reduction of inflammatory cytokines [interleukin (IL)-1, IL-6, IL-8 and/or tumor necrosis factor-&#x3b1;], authors also observed inhibitions of the nuclear factor-kappa B (NF-&#x3ba;B) (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.01186">Balkrishna et al.</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.00180">Cui et al.</ext-link>) and improvement of the total antioxidant capacity (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.00180">Cui et al.</ext-link>), superoxide dismutase (SOD) (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.00180">Cui et al.</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2018.01268">Ibrahim et al.</ext-link>), catalase (CAT) (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2018.01268">Ibrahim et al.</ext-link>), and glutathione peroxidase (GSH-Px) (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.00180">Cui et al.</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2018.01268">Ibrahim et al.</ext-link>).</p>
<p><ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2019.01647/abstract">Patti et al.</ext-link> reported the antioxidant activity of <italic>Mentha longifolia L</italic>. crude extract <italic>in vitro</italic> and the antiproliferative effects on two adrenocortical tumor cell models. On the other hand, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.00486">Bortolotti et al.</ext-link> pointed out that most existing studies on <italic>Momordica charantia</italic> (commonly called bitter melon) bioactive compounds were performed only on cell lines and in animal models and that clinical studies are needed to establish its efficacy and safety in patients. Besides, both <italic>in vitro</italic> and <italic>in vivo</italic> studies demonstrated that bitter melon may also elicit toxic or adverse effects under different conditions and few papers discuss the anti-inflammatory and anticancer properties. Moreover, in a systematic review, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.00675">Medic et al.</ext-link> concluded that despite anthocyanins-enriched diets proved to be effective in experimental murine models of colorectal cancer, no effect in human studies was observed. A hypothesis for the different effect in murine models and human could be the relationship among nutraceuticals and microbiota (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.00492">Vamanu</ext-link>). From that, personalized health care for chronic noncommunicable diseases that impact quality of life should consider gut microbiota in addition to genetic and epigenetic factors, health status, polypharmacy, and moods (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2019.00994">Sciarra et al.</ext-link>).</p>
<sec id="s3">
<title>Author Contributions</title>
<p>All authors listed have made substantial, direct, and intellectual contribution to the work, and approved it for publication.</p>
</sec>
<sec id="s4">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
</article>